Please login to the form below

Not currently logged in
Email:
Password:

Kyndrisa

This page shows the latest Kyndrisa news and features for those working in and with pharma, biotech and healthcare.

Santhera facing long delay for muscular dystrophy drug in US

Santhera facing long delay for muscular dystrophy drug in US

In recent months the FDA has rejected BioMarin's exon-skipping therapy Kyndrisa (drisapersen) - which has now been abandoned after also being turned down by the EMA - as well as PTC

Latest news

More from news
Approximately 3 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Healthcare Media Europe – HME Ltd

HME are an innovative and technology enabled agency offering our clients over 35+ years of knowledge and expertise in delivering...

Latest intelligence

Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....
The rise of vertical integration in the US payer landscape
Is it a solution to addressing the challenges of the value-based marketplace?...
Light_bulb_Stock_Market.jpg
Creativity has lost its worth
Creativity has lost its worth, and sadly it is undermining effectiveness...

Infographics